Sanofi FR Stock Price, News & Analysis

Sanofi has launched AVAXIM® Junior in the UK, an inactive hepatitis A vaccine aimed at children aged 12 months to 15 years. The vaccination entails two doses administered intramuscularly, ideally spaced between 6 to 36 months but can extend to 7 years. The launch is supported by data from 20 clinical studies across 14 countries, involving more than 6,200 children, demonstrating over 95% efficacy in inducing a protective antibody response within two weeks. AVAXIM Junior addresses the prevalence of hepatitis A, a common travel-related disease, providing parents with reassurance when traveling to high-risk areas. Side effects typically include soreness at the injection site and general malaise. Sanofi, listed on Euronext and NASDAQ as SNY, aims to enhance global health through innovative treatments and vaccine options.

Sanofi and BARDA celebrated the groundbreaking of a new formulation and filling facility in Swiftwater, Pennsylvania, on April 4, 2023. This state-of-the-art facility, supported by federal funds, aims to enhance the manufacturing of pandemic influenza vaccines. It will include cutting-edge technology for syringe and vial filling, contributing to Sanofi's commitment to pandemic preparedness. The project complements a contract awarded in December 2019 to boost domestic vaccine production capabilities. Sanofi plans to utilize advanced recombinant technology, expanding its capacity to deliver effective vaccines during pandemics.

Sanofi has introduced the Sanofi NextGen Scholarship at the 53rd Annual Meeting of the World Economic Forum in Davos. This global initiative aims to support students from underrepresented communities pursuing careers in healthcare. Starting in Brazil, France, Japan, the UK, and the U.S., the program will award funding for up to 100 selected students annually, covering tuition and living costs. The scholarship also includes mentorship and internship opportunities. Sanofi's initiative follows a global survey revealing significant trust issues in healthcare among underrepresented populations, highlighting a need for greater diversity in healthcare roles.

Regeneron Pharmaceuticals and Sanofi announced that a Phase 3 trial of Dupixent (dupilumab) 300 mg weekly for treating eosinophilic esophagitis (EoE) showed significant improvements in patient histology and symptoms compared to placebo. Improvements were sustained for up to one year in patients aged 12 and older. Dupixent is the first U.S. approved targeted treatment for EoE. The FDA approved Dupixent in May 2022, and the EMA has given a positive opinion for its use in Europe. Safety results matched Dupixent's known profile, suggesting a favorable risk-benefit ratio.

Innate Pharma (Euronext: IPH; Nasdaq: IPHA) has expanded its collaboration with Sanofi (NASDAQ: SNY) by granting an exclusive license for its B7H3 ANKET^TM program. Sanofi will be accountable for all development and commercialization activities. Innate will receive an upfront payment of €25 million and up to €1.35 billion in potential milestones, along with royalties from net sales. This partnership continues the 2016 collaboration focused on NK cell engagers, enhancing Innate's cancer treatment portfolio and Sanofi's oncology strategy.

Regeneron Pharmaceuticals and Sanofi announced that the European Medicines Agency's Committee has recommended Dupixent for approval to treat adolescents and adults aged 12 and over with eosinophilic esophagitis (EoE). This would make Dupixent the first targeted treatment for EoE in the EU, following its U.S. approval in May 2022. The positive recommendation is based on pivotal trial data showing significant improvements in patients' ability to swallow and histological remission. The European Commission will make a final decision soon.